The total return for UCB (EBR:UCB) investors has risen faster than earnings growth over the last three years

It hasn't been the best quarter for UCB SA (EBR:UCB) shareholders, since the share price has fallen 12% in that time. But that doesn't change the fact that the returns over the last three years have been pleasing. In the last three years the share price is up, 93%: better than the market.

While the stock has fallen 3.6% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

UCB was able to grow its EPS at 0.1% per year over three years, sending the share price higher. This EPS growth is lower than the 25% average annual increase in the share price. This suggests that, as the business progressed over the last few years, it gained the confidence of market participants. It's not unusual to see the market 're-rate' a stock, after a few years of growth.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
ENXTBR:UCB Earnings Per Share Growth June 20th 2025

We know that UCB has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

Advertisement

What About Dividends?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, UCB's TSR for the last 3 years was 98%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

A Different Perspective

It's good to see that UCB has rewarded shareholders with a total shareholder return of 16% in the last twelve months. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 10% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with UCB , and understanding them should be part of your investment process.

We will like UCB better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Belgian exchanges.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTBR:UCB

UCB

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0768.0% undervalued
274 users have followed this narrative
1 users have commented on this narrative
37 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.5% undervalued
15 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
TO
Tokyo
ABI logo
Tokyo on Anheuser-Busch InBev ·

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

Fair Value:€89.4522.8% undervalued
1 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative
OS
oscargarcia
AMZN logo
oscargarcia on Amazon.com ·

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.

Fair Value:US$2802.3% undervalued
56 users have followed this narrative
1 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

WO
woodworthfund
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4050.1% undervalued
35 users have followed this narrative
7 users have commented on this narrative
0 users have liked this narrative
CO
Coward_Nutlick
ELTX logo
Coward_Nutlick on Elicio Therapeutics ·

Very Bullish

Fair Value:US$10089.4% undervalued
20 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
PWR logo
HedgeY on Quanta Services ·

The Picks-and-Shovels Leader of the Grid Supercycle

Fair Value:US$7108.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.235.6% undervalued
68 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9326.8% undervalued
1394 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74018.2% undervalued
31 users have followed this narrative
3 users have commented on this narrative
32 users have liked this narrative

Trending Discussion